Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Finerenone with empagliflozin according to body mass index in chronic kidney disease and type 2 diabetes
- Benefits of empagliflozin + finerenone on UACR reduction, versus each therapy individually, were consistent irrespective of BMI.
- Modest reductions in body weight were observed with all treatments, and may be an important ancillary benefit in this population.
- Greater reductions in body weight were associated with a higher probability of achieving a ≥30% UACR reduction by Day 180 .
These findings support the use of empagliflozin and finerenone to maximize UACR lowering in persons with CKD and T2D, irrespective of BMI.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
